Core Insights - The recent conference in Suzhou focused on advancements in the diagnosis and treatment of Acute Lymphoblastic Leukemia (ALL), aiming to enhance the standard of care in Jiangsu Province [1][2] - ALL accounts for 30% to 40% of acute leukemia cases, primarily affecting adults aged 30 to 40, with poor prognosis for patients over 40 and those with relapsed or refractory cases [1] Group 1: Current Status and Challenges - Significant improvements in survival rates for ALL patients have been observed due to advancements in treatment technologies, including bispecific antibodies and CAR T-cell therapy [2] - Despite these advancements, there are still unmet needs in clinical diagnosis and treatment, particularly in grassroots medical institutions, leading to a lack of standardized care for many patients [2] Group 2: Initiatives and Future Directions - The Jiangsu ALL Working Group has been established to explore standardized treatment pathways and improve overall care quality, focusing on the development of clinical pathways for ph+/ph- B-ALL [2] - The group aims to enhance regional diagnostic and treatment levels through regular academic exchanges, case consultations, and research initiatives, ultimately striving for a uniform standard of care across the province [2][3] - Future efforts will include optimizing standardized treatment pathways and promoting the "Jiangsu experience" nationwide to improve ALL care for more patients [3]

Core Insights - The article discusses the increase of abdominal fat with age, highlighting its health risks such as diabetes and heart disease [1][2] - A recent study from the "City of Hope" National Medical Center reveals that aging fat cell progenitors (APCs) become more active, leading to increased fat cell production [1] - The study identifies a specific signaling pathway, leukemia inhibitory factor receptor (LIFR), that drives the transformation of APCs into more powerful "super craftsmen" known as age-specific preadipocytes (CP-As) [2] Group 1 - Aging leads to the transformation of fat cell progenitors (APCs) that become more active and produce more fat cells, contributing to abdominal obesity [1] - The emergence of age-specific preadipocytes (CP-As) during middle age explains the increase in waist circumference even without significant weight gain [2] - The LIFR signaling pathway is crucial for the proliferation of CP-As, which results in the accumulation of abdominal fat [2] Group 2 - The findings provide insights into the mechanisms behind age-related obesity and suggest potential therapeutic approaches to combat this issue [2]

Core Insights - A recent study led by Professor Wang Jian'an's team compared the clinical outcomes of coronary angiography-derived fractional flow reserve (FFR) guided intervention strategies with intravascular ultrasound (IVUS) guided strategies in patients with coronary artery disease (CAD) [1][2] - The study found that in non-complex CAD patients, the angiography-derived FFR guided intervention strategy is not inferior to the IVUS guided strategy in clinical outcomes and has the advantage of reducing stent implantation [1] Group 1 - Coronary artery disease is a major global health threat caused by narrowing or blockage of coronary arteries, leading to myocardial ischemia and related conditions [1] - Fractional flow reserve is a critical functional indicator for assessing coronary blood flow, essential for developing appropriate treatment strategies in CAD interventions [1] Group 2 - Traditional invasive FFR is widely recognized but is complex and carries certain risks, while IVUS provides direct visualization of vascular structures but is also an invasive procedure [2] - The emergence of imaging-derived FFR technology offers a non-invasive alternative that simplifies the procedure, requiring only angiography without additional guidewires or vasodilators [2] - The study provides a simpler decision-making and optimization tool for percutaneous coronary intervention, contributing strong evidence for future updates to cardiovascular intervention guidelines [2]

德岛大学医院开发的方法是将利用患者自己的干细胞制成的胰岛素生成细胞移植给患者，以补充 胰岛素。据悉移植后几乎不会出现排异反应，且不像iPS细胞那样需要进行基因导入，不易产生 基因错误…… 日本德岛大学医院的池本哲也教授等人3月24日表示，最早将于2025年夏季开始临床试验，利用从患者 自己的脂肪中提取的干细胞来治疗1型糖尿病。通过特殊方式将干细胞培养成胰岛素生成细胞，并将其 移植给患者，以期根治糖尿病。力争在2030年左右实现实用化。 1型糖尿病是一种因自身免疫反应导致降低血糖的胰岛素生成细胞受损的疾病，据推算日本国内有10万 ~14万患者。这种疾病多发于年轻人，与受生活习惯影响的2型糖尿病不同。患者可能出现失明及心肌 梗塞等并发症，需要自行注射胰岛素。 关于1型糖尿病的治疗，日本京都大学医院也计划2025年开始移植利用iPS细胞制成的分泌胰岛素的胰岛 细胞的临床试验，治疗方法的开发竞争日益激烈。 德岛大学医院的池本教授谈到自己团队开发的方法表示："由于是来自自己的细胞，移植后几乎不会出 现排异反应，且不像iPS细胞那样需要进行基因导入，因此不易产生基因错误，这是一大优势"。 版权声明：日本经济新闻社版权所有 ...